
A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.
Novel immunotherapy demonstrates Long-Lasting benefits HRP Ovarian Cancer
21 minutes of daily walk could save your health
A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.